anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Company profile
Ticker
AVXL
Exchange
Website
CEO
Christopher Missling
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Thrifty Printing Inc.
SEC CIK
Corporate docs
Subsidiaries
Anavex Australia Pty Limited • Anavex Germany GmbH • Anavex Canada Ltd. ...
AVXL stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 Feb 24
10-K
2023 FY
Annual report
27 Nov 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
24 May 23
10-Q
2023 Q2
Quarterly report
9 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Other Events
7 Feb 23
Transcripts
AVXL
Earnings call transcript
2024 Q1
7 Feb 24
AVXL
Earnings call transcript
2023 Q3
8 Aug 23
AVXL
Earnings call transcript
2023 Q2
9 May 23
AVXL
Earnings call transcript
2023 Q1
7 Feb 23
AVXL
Earnings call transcript
2022 Q4
28 Nov 22
AVXL
Earnings call transcript
2022 Q3
9 Aug 22
AVXL
Earnings call transcript
2022 Q2
10 May 22
AVXL
Earnings call transcript
2022 Q1
9 Feb 22
AVXL
Earnings call transcript
2021 Q4
25 Nov 21
AVXL
Earnings call transcript
2021 Q3
13 Aug 21
Latest ownership filings
4
CHRISTOPHER U MISSLING
1 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Peter D.O. Donhauser
23 Feb 24
4
Steffen Thomas
23 Feb 24
4
Claus Vander Velden
23 Feb 24
4
Jiong Ma
23 Feb 24
4
Athanasios Skarpelos
23 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 151.02 mm | 151.02 mm | 151.02 mm | 151.02 mm | 151.02 mm | 151.02 mm |
Cash burn (monthly) | 1.26 mm | (no burn) | 4.22 mm | 4.65 mm | 1.95 mm | 2.32 mm |
Cash used (since last report) | 8.43 mm | n/a | 28.12 mm | 30.98 mm | 13.00 mm | 15.44 mm |
Cash remaining | 142.59 mm | n/a | 122.90 mm | 120.04 mm | 138.02 mm | 135.58 mm |
Runway (months of cash) | 112.8 | n/a | 29.1 | 25.8 | 70.8 | 58.6 |
Institutional ownership, Q3 2023
30.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 17 |
Closed positions | 17 |
Increased positions | 52 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 159.36 bn |
Total shares | 25.04 mm |
Total puts | 1.17 mm |
Total calls | 859.20 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.06 mm | $39.70 bn |
Vanguard | 4.25 mm | $27.81 bn |
STT State Street | 3.63 mm | $23.75 bn |
Geode Capital Management | 1.57 mm | $10.30 bn |
NTRS Northern Trust | 751.37 k | $4.92 bn |
Millennium Management | 723.50 k | $4.74 bn |
Nwam | 720.99 k | $4.72 bn |
Charles Schwab Investment Management | 604.81 k | $3.96 bn |
Citadel Advisors | 575.11 k | $3.77 bn |
Susquehanna International | 445.91 k | $2.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Christopher U Missling | Common Stock | Sell | Dispose S | No | No | 5.11 | 73,380 | 374.97 k | 1,250,210 |
28 Mar 24 | Christopher U Missling | Common Stock | Option exercise | Acquire M | No | No | 1.32 | 73,380 | 96.86 k | 1,323,590 |
28 Mar 24 | Christopher U Missling | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.32 | 73,380 | 96.86 k | 0 |
20 Feb 24 | Peter D.O. Donhauser | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 50,000 | 268.00 k | 50,000 |
20 Feb 24 | Steffen Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 50,000 | 268.00 k | 50,000 |
20 Feb 24 | Claus Vander Velden | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 50,000 | 268.00 k | 50,000 |
20 Feb 24 | Jiong Ma | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 50,000 | 268.00 k | 50,000 |
News
Anavex Life Sciences Q1 EPS $(0.11) Beats $(0.14) Estimate; Cash And Cash Equivalents Of $143.8M
7 Feb 24
Earnings Scheduled For February 7, 2024
7 Feb 24
Anavex Life Sciences Earnings Preview
6 Feb 24
Peering Into Anavex Life Sciences's Recent Short Interest
24 Jan 24
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
23 Jan 24
Press releases
Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL)
19 Apr 24
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit
18 Apr 24
Lost Money on Anavex Life Sciences Corporation (AVXL)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
18 Apr 24
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
18 Apr 24
May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL
17 Apr 24